EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Anti-Claudin Treatments in Gastroesophageal Adenocarcinoma: Mainstream and Upcoming Strategies

Giulia Grizzi, Kostantinos Venetis, Nerina Denaro iD, Maria Bonomi, Andrea Celotti, Antonia Pagkali iD, Jens Claus Hahne, Gianluca Tomasello, Fausto Petrelli iD, Nicola Fusco iD, Michele Ghidini iD

Journal of Clinical Medicine · 19.04.2023 · 12 (8) · 2973

DOI: 10.3390/jcm12082973 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Clinical Medicine, online erschienen am 19.04.2023. Verfasst von Giulia Grizzi und 10 weiteren Autor:innen. Beteiligte Einrichtung: Operative Unit of Oncology, ASST of Cremona, 26100 Cremona, Italy. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Claudins (CLDNs) are a multigene family of proteins and the principal components of tight junctions (TJs), which normally mediate cell–cell adhesion and selectively allow the paracellular flux of ions and small molecules between cells. Downregulation of claudin proteins increases the paracellular permeability of nutrients and growth stimuli to malignant cells, which aids the epithelial transition. Claudin 18.2 (CLDN18.2) was identified as a promising target for the treatment of advanced gastroesophageal adenocarcinoma (GEAC), with high levels found in almost 30% of metastatic cases. CLDN18.2 aberrations, enriched in the genomically stable subgroup of GEAC and the diffuse histological subtype, are ideal candidates for monoclonal antibodies and CAR-T cells. Zolbetuximab, a highly specific anti-CLDN18.2 monoclonal antibody, demonstrated efficacy in phase II studies and, more recently, in the phase III SPOTLIGHT trial, with improvements in both PFS and OS with respect to standard chemotherapy. Anti-CLDN18.2 chimeric antigen receptor (CAR)-T cells showed a safety profile with a prevalence of hematologic toxicity in early phase clinical trials. The aim of this review is to present new findings in the treatment of CLDN18.2-positive GEAC, with a particular focus on the monoclonal antibody zolbetuximab and on the use of engineered anti-CLDN18.2 CAR-T cells.

Schlagwörter

Stichwörter der Autor:innen

anti-claudin 18.2car-T cellschemotherapyclaudinsesophageal cancergastric cancerzolbetuximab

Autor:innen und Institutionen

  • Operative Unit of Oncology, ASST of Cremona, 26100 Cremona, Italy.
  • Division of Pathology, IEO, European Institute of Oncology IRCCS, 20141 Milan, Italy.
  • Department of Oncology and Hemato-Oncology, University of Milan, 20122 Milan, Italy.
  • Oncology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, 20122 Milan, Italy.
  • Department of Surgery, ASST of Cremona, 26100 Cremona, Italy.
  • School of Medicine, National and Kapodistrian University of Athens, 11527 Athens, Greece.

ORCID-Profile: Nerina Denaro, Antonia Pagkali, Fausto Petrelli, Nicola Fusco, Michele Ghidini

Zitieren

APA

Grizzi, G., Venetis, K., Denaro, N., Bonomi, M., Celotti, A., Pagkali, A., Hahne, J. C., Tomasello, G., Petrelli, F., Fusco, N., & Ghidini, M. (2023). Anti-Claudin Treatments in Gastroesophageal Adenocarcinoma: Mainstream and Upcoming Strategies. Journal of Clinical Medicine, 12(8), 2973. https://doi.org/10.3390/jcm12082973

Vancouver

Grizzi G, Venetis K, Denaro N, Bonomi M, Celotti A, Pagkali A, et al. Anti-Claudin Treatments in Gastroesophageal Adenocarcinoma: Mainstream and Upcoming Strategies. Journal of Clinical Medicine. 2023;12(8):2973. doi:10.3390/jcm12082973

BibTeX
@article{Grizzi2023,
  author = {Grizzi, Giulia and Venetis, Kostantinos and Denaro, Nerina and Bonomi, Maria and Celotti, Andrea and Pagkali, Antonia and Hahne, Jens Claus and Tomasello, Gianluca and Petrelli, Fausto and Fusco, Nicola and Ghidini, Michele},
  title = {Anti-Claudin Treatments in Gastroesophageal Adenocarcinoma: Mainstream and Upcoming Strategies},
  journal = {Journal of Clinical Medicine},
  year = {2023},
  volume = {12},
  number = {8},
  pages = {2973},
  doi = {10.3390/jcm12082973}
}
Kostenlos starten →